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OBJECTIVE — Acute glycemic variability contributes to diabetic complications potentially
through induction of inﬂammation. Our objective was to determine whether acute hyperglyce-
mia affects urinary secretion of inﬂammatory cytokines/chemokines in humans with uncompli-
cated type 1 diabetes.
RESEARCHDESIGNANDMETHODS — Bloodpressure,renalhemodynamics(inulin
and paraaminohippurate clearances), and urine samples were obtained after6ho fclamped
euglycemia (4–6 mmol/l) and hyperglycemia (9–11 mmol/l) on two consecutive days in sub-
jects with type 1 diabetes (n  25). Forty-two urinary cytokines/chemokines were measured
using a Luminex platform.
RESULTS — Clamped hyperglycemia produced an expected increase in glomerular ﬁltration
rate (131  4t o1 4 8 8 ml/min/1.73 m
2). Clamped hyperglycemia was associated with
signiﬁcant increases in urinary eotaxin, ﬁbroblast growth factor-2, granulocyte-macrophage
colony-stimulating factor, interferon- 2, interleukin-2 and -12, monocyte chemoattractant
protein-3, macrophage-derived chemokine, macrophage inﬂammatory protein-1, platelet-
derived growth factor, tumor necrosis factor-, and CD40 ligand (P  0.05).
CONCLUSIONS — Acute hyperglycemia results in increased urinary excretion of inﬂam-
matory cytokines/chemokines in humans with uncomplicated type 1 diabetes, and this may
contribute to kidney injury.
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E
mergingevidencesuggeststhatacute
glycemic excursions may signiﬁ-
cantly contribute to microvascular
end-organ injury in patients with diabe-
tes, independent of long-term glycemic
control (1). While the mechanisms ac-
counting for this observation are not com-
pletely understood, evidence suggests that
acute hyperglycemia affects systemic and
renal microvascular hemodynamic func-
tion and activates systemic inﬂammatory
pathways (2–6). The effect of acute
clampedhyperglycemiaonrenalinﬂamma-
tory mediators, however, is not completely
understood (7–9). Accordingly, our goal
was to characterize the earliest effects of
acutehyperglycemiaontheactivationofre-
nalinﬂammatorypathwaysinpatientswith
uncomplicated type 1 diabetes in order to
better understand how acute glycemic ex-
cursions may independently contribute to
long-term kidney injury.
RESEARCH DESIGN AND
METHODS— Recruitment of a subset
ofsubjectsinthiscohorthasbeendescribed
in detail elsewhere (supplementary Table
A1,availableinanonlineappendixathttp://
care.diabetesjournals.org/cgi/content/full/
dc10-1219/DC1) (10). Subjects adhered to
a sodium replete (140 mmol/day) and
moderateprotein(1.5g/kg/day)dietdur-
ing the 7-day period before each experi-
ment (10,11). A 24-h urine collection on
day 6 was used to evaluate dietary adher-
ence through the determination of urinary
sodium and urea excretion. Protein intake
was calculated from the urea excretion us-
ing standard methods (10,11).
Ontwoconsecutivedays,brachialar-
tery blood pressure, renal hemodynamic
parameters, and a spot urine sample were
obtained after a 6-h modiﬁed clamp, dur-
ing euglycemia (day 1, 4–6 mmol/l), and
hyperglycemia (day 2, 9–11 mmol/l)
(10,11). In the left arm, a peripheral ve-
nous cannula was inserted for infusion of
glucoseandinsulin,andasecondcannula
wasinsertedforbloodsamplingmoredis-
tally. At the same time, a third intrave-
nous infusion was inserted into the right
arm and connected to a syringe infusion
pump to measure renal hemodynamic
function.
Blood pressure measurements were
obtained with an automated Dinamap
sphygmomanometer (Critikon, Tampa,
FL). Renal hemodynamic function (glo-
merular ﬁltration rate and effective renal
plasma ﬂow) were estimated by steady-
state infusion of inulin and paraamin-
ohippurate (10,11).
Urinary analytes were measured in
each urine sample using the 42-Plex Pri-
mary Cytokine/Chemokine Panel Lumi-
nex Assay (Eve Technologies, Calgary,
Alberta, Canada) and included: epider-
mal growth factor, eotaxin, ﬁbroblast
growth factor-2, Fit-3L, fractalkine, gran-
ulocyte colony stimulation factor, granu-
locyte-macrophage colony-stimulating
factor, growth-regulated oncogene, inter-
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1, IL-1, IL-1ra, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40),
IL-12 (p70), IL-13, IL-15, IL-17, IP-10,
monocyte chemoattractant protein
(MCP)-1, MCP-3, macrophage-derived
chemokine, macrophage inﬂammatory
protein (MIP)-1, MIP-1, platelet-
derived growth factor (PDGF)-AA,
PDGF-AB/BB, RANTES, sCD40K, sIL-
2R, transforming growth factor-, tu-
mor necrosis factor (TNF)-, TNF-,
and vascular endothelial growth factor
(supplementary Table A2). Analytes
were corrected for the urinary creati-
nine concentration.
Baseline clinical parameters were an-
alyzedusingparametricmethods(twoin-
dependent sample t tests). Within subject
responses to hyperglycemia were deter-
mined by repeated measures analysis of
variance and were corrected for multiple
comparisons using the Tukey-Kramer
test. All statistical analyses were per-
formed using SAS 9.2. The University
Health Network and Hospital for Sick
Children (Toronto, Canada) Research
Ethics Boards approved the protocols,
and patients gave informed consent.
RESULTS— Supplementary Table A3
describestheclinicalcharacteristicsofthe
cohort (n  25). Subjects were young,
normotensive, normoalbuminuric men
andwomenwithtype1diabetes.Subjects
adhered to the controlled sodium and
protein diet. Six hours of clamped hyper-
glycemiawasassociatedwithexpectedin-
creases in glomerular ﬁltration rate and
effective renal plasma ﬂow (P  0.05).
Clamped hyperglycemia was also as-
sociated with signiﬁcant increases in uri-
nary eotaxin (P  0.0075), ﬁbroblast
growth factor-2 (P  0.0026), granulo-
cyte-macrophage colony-stimulating fac-
tor (P  0.0192), IFN-2( P  0.0045),
IL-12 (P  0.0034), MCP-3 (P 
0.0062), macrophage-derived chemo-
kine(P0.0111),MIP-1(P0.0201),
PDGF-AB/BB (P  0.0267), TNF- (P 
0.0049), sCD40K (P  0.0080) (Fig. 1A–
L). For IL-3, the unadjusted P value was
0.01, which was not signiﬁcant after ad-
justment for multiple comparisons (P 
0.058).
CONCLUSIONS — The goal of this
pilot study was to determine whether
acute clamped hyperglycemia activates
renal inﬂammatory pathways in patients
with uncomplicated type 1 diabetes. Our
rationale was twofold: 1) acute glycemic
excursions may contribute to end-organ
injury in patients with diabetes, indepen-
dent of long-term glycemic control; and
2) while acute hyperglycemia is associ-
ated with hemodynamic changes and ac-
tivation of systemic inﬂammation, the
acute effects on renal inﬂammatory path-
waysarenotdescribedwell.Wetherefore
determinedwhetheracutehyperglycemia
may contribute to kidney injury by acti-
vation of inﬂammatory pathways in pa-
tientswithuncomplicatedtype1diabetes
by measuring renal hemodynamic func-
tion and urinary concentrations of a broad
panel of cytokines/chemokines in response
to acute clamped hyperglycemia.
Our major ﬁnding was that in sub-
jects with uncomplicated type 1 diabetes,
clampedhyperglycemiaisassociatedwith
signiﬁcant increases in 12/42 cytokines/
chemokines included in the pilot study.
Urinary cytokines/chemokines excretion
is increased in established diabetic ne-
phropathy, and their excretion is inﬂu-
enced by renoprotective medications
(7,8,12–14). Less is known about the re-
Figure1—Theeffectofhyperglycemiaonurinarychemokines/cytokines(meanSD).*P0.05
compared with clamped euglycemia.
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in response to acute clamped hyperglyce-
mia in humans with uncomplicated type
1 diabetes (15). Our ﬁndings show that
acute moderate hyperglycemia induces
anincreaseinurinaryexcretionofinﬂam-
matory mediators. While the factors re-
sponsible for this rise were not
determined in this study, possible mech-
anismsincludesynthesisand/orreleaseof
preformed cytokines/chemokines from
the kidney or possible spillover from the
systemic circulation.
Given the critical role for hyperglyce-
mia in the pathogenesis of diabetic ne-
phropathy, the acute effect of glucose on
markers of inﬂammation and ﬁbrosis is
important for two key reasons. First, in-
creases in the urinary excretion of inﬂam-
matory factors may give mechanistic
insights into disease pathogenesis in hu-
mans at a preclinical stage of disease. Our
observations are consistent with previous
work that demonstrated the deleterious
effects of acute glycemic excursions on
the renal microvasculature and highlight
biologicalpathwaysthatmaybeinvolved.
Second,mediatorsthatincreaseunderthe
inﬂuence of acute hyperglycemia may act
asmarkersthatcanbeusedtomonitorthe
biological effects of experimental and
therapeutic interventions in patients with
type 1 diabetes. Although our study in-
volved a small cohort that may never de-
velop clinical diabetic nephropathy, our
ﬁndingssuggestthatacutehyperglycemia
inducesadynamicmolecularsignalinthe
urine that may contribute to progressive
kidney injury over time. Future work
should involve deﬁning the time course
and reversibility of the response and
studying other populations, including
nondiabetic control subjects and patients
with overt nephropathy.
In conclusion, acute moderate hyper-
glycemia is associated with signiﬁcant in-
creases in the urinary excretion of
inﬂammatory cytokines/chemokines in
subjects with uncomplicated type 1
diabetes.
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